Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Board member resigns from Griffin Mining's HHA subsidiary

(Sharecast News) - Griffin Mining announced the resignation of Shengchang Jin from his position as a director of Hebei Hua Ao Mining (HHA), an operating subsidiary owned 88.8% by the company, on Friday. The AIM-traded firm said that effective 7 January, a termination agreement had been formalised, signifying the cessation of Jin's involvement with HHA in any capacity.

Regarding Jin's potential legal actions in the People's Republic of China concerning his role as chief executive officer of Zhangjiakou Yuanrun Enterprise Management Consulting Service, a minority 11.2% shareholder in HHA, Griffin said it had remained uninformed since its announcement on 15 December.

It reiterated that ongoing investigations solely concerned Jin and did not implicate HHA's operations or relevant statutory licences granted by the government.

At 0915 GMT, shares in Griffin Mining were down 0.56% at 96.46p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

UBS to book $900m provision over Greensill supply financing funds
(Sharecast News) - Swiss banking giant UBS announced on Monday that it expected to book a provision of about $900m related to Credit Suisse's funds, tied to the collapsed supply chain financing firm Greensill Capital.
Citi downgrades European equities to 'neutral'
(Sharecast News) - Citi downgraded its stance on European equities on Monday to 'neutral' from 'overweight' as it said near-term risks have increased, with markets narrowing and political uncertainty taking centre stage.
Hutchmed publishes positive sovleplenib trial results
(Sharecast News) - Hutchmed China announced the publication of positive results from its phase three 'ESLIM-01' trial of sovleplenib in the Lancet Haematology.
Somero trading in line with expectations
(Sharecast News) - Somero Enterprises said in an update on Monday that trading for the first five months of 2024 was consistent with expectations.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.